Literature DB >> 3987771

Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

D Tinguely, P Baumann, M Conti, M Jonzier-Perey, J Schöpf.   

Abstract

Alpha 1-acid glycoprotein (AAG) is one of the plasma proteins that bind basic drugs, like amitriptyline (AT) and its metabolite nortriptyline (NT). Two types of genetic polymorphism have been described for AAG: polymorphic forms which, on electrophoresis of the native protein, give four patterns with 5, 6, 7 or 8 bands, and the variants which on by electrophoresis of the desialysed protein, give three patterns with 2 bands, FF, FS and SS. In 31 depressive patients, treated daily with 150 mg AT for 3 weeks, free and total plasma AT and NT were determined, as well as the AAG polymorphic forms and variants. There was only a weak negative correlation between the free fractions of AT and NT and total plasma AAG, but free AT and NT were strongly correlated with the S form (but not the F form) of AAG variants. The differences in binding might be the expression of a further genetic factor determining the steady-state plasma levels of tricyclic drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987771     DOI: 10.1007/bf00547045

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  THE ALPHA-1-ACID GLYCOPROTEIN VARIANTS OF NORMAL CAUCASIAN AND JAPANESE INDIVIDUALS.

Authors:  K SCHMID; K TOKITA; H YOSHIZAKI
Journal:  J Clin Invest       Date:  1965-08       Impact factor: 14.808

2.  Studies on the mucoproteins of human plasma. V. Isolation and characterization of a homogeneous mucoprotein.

Authors:  H E WEIMER; J W MEHL; R J WINZLER
Journal:  J Biol Chem       Date:  1950-08       Impact factor: 5.157

3.  Binding of psychotropic drugs to isolated alpha-acid glycoprotein.

Authors:  M L Kornguth; L G Hutchins; B S Eichelman
Journal:  Biochem Pharmacol       Date:  1981-09-01       Impact factor: 5.858

4.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  Plasma protein binding of tricyclic anti-depressants in man.

Authors:  O Borgå; D L Azarnoff; G P Forshell; F Sjöqvist
Journal:  Biochem Pharmacol       Date:  1969-09       Impact factor: 5.858

6.  The binding of chemically different psychotropic drugs to alpha 1-acid glycoprotein.

Authors:  J Schley; B Müller-Oerlinghausen
Journal:  Pharmacopsychiatria       Date:  1983-05

7.  Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site.

Authors:  T Kute; U Westphal
Journal:  Biochim Biophys Acta       Date:  1976-01-20

8.  Determination of the primary structures of 16 asialo-carbohydrate units derived from human plasma alpha 1-acid glycoprotein by 360-MHZ 1H NMR spectroscopy and permethylation analysis.

Authors:  B Fournet; J Montreuil; G Strecker; L Dorland; J Haverkamp; F G Vliegenthart; J P Binette; K Schmid
Journal:  Biochemistry       Date:  1978-11-28       Impact factor: 3.162

9.  A sensitive method for the determination of amitriptyline and nortriptyline in human plasma.

Authors:  T B Cooper; D Allen; G M Simpson
Journal:  Psychopharmacol Commun       Date:  1976

10.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

View more
  15 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.

Authors:  J L Pinquier; S Urien; P Chaumet-Riffaud; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

5.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

6.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 7.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

8.  Entrapment of alpha1-acid glycoprotein in high-performance affinity columns for drug-protein binding studies.

Authors:  Cong Bi; Abby Jackson; John Vargas-Badilla; Rong Li; Giana Rada; Jeanethe Anguizola; Erika Pfaunmiller; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-11-27       Impact factor: 3.205

9.  Orosomucoid (ORM) typing by isoelectric focusing: evidence for gene duplication of ORM1 and genetic polymorphism of ORM2.

Authors:  I Yuasa; K Suenaga; K Umetsu; K Ito; M Robinet-Levy
Journal:  Hum Genet       Date:  1987-11       Impact factor: 4.132

10.  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

Authors:  Lian Sheng Wang; Jing Jing Shang; Shu Ya Shi; Yan Qing Zhang; Jian Lin; Zhi Hua Guo; Yi Chen Wang; Jie Tang; Jie Liu; Ying Zi Liu; Zhi Li; Zhi Rong Tan; Hong Hao Zhou; Hai He Jiang; Hai Tang Xie
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.